Bankruptcy court approves Insys Therapeutics to sell opioidChristian Fernsby ▼ | October 19, 2019
Insys Therapeutics got court approval to sell its flagship fentanyl spray to a buyer who agreed to only market the drug for use by cancer patients.
America Insys Therapeutics
Topics: Ban Insys Therapeutics opioid
The ruling cleared the way for the drug, Subsys, to be sold to Wyoming-based BTcP Pharma LLC, which belongs to the MMB Healthcare network of pharmaceutical companies. In exchange, Insys will receive royalties it estimated could reach $20 million. That will raise money to satisfy creditors.
“Obviously all were concerned with the purchaser of the product,” Gross said. “There is a crisis in this country and we’re all still trying to get a handle on it.” ■